1 / 13

Oracle’s position in the Life Sciences Industry

Oracle’s position in the Life Sciences Industry. Charles Scatchard, Vice President Healthcare and Life Sciences EMEA Oracle France Pharma Day Paris, October 13 th , 2005. The LS value chain. Discovery. Suppliers. Payers / Regulators. Pharmaceutical. Public/ Private Data.

nayda-cobb
Download Presentation

Oracle’s position in the Life Sciences Industry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oracle’s position in the Life Sciences Industry Charles Scatchard, Vice President Healthcare and Life Sciences EMEA Oracle France Pharma Day Paris, October 13th, 2005

  2. The LS value chain Discovery Suppliers Payers / Regulators Pharmaceutical Public/Private Data Distributor/Wholesaler Development Medical Eqpt SampleData In Silico Pharmaceutical Company Biotech Employer Wet Lab Pharmaceutical Company Other Pre-Clinical Trials Payer Biotech /PharmaceuticalResearch Labs Outpatient Pharmaceutical Mfg Plant Retailer Clinical Trials RegulatoryAgency Primary Care BiomedicalFirm BiomedicalFirm Hospitals Contract Research Organization Physicians RegulatoryAgency Distribution IntegratedNetworks Pharmacy Patients Providers Manufacturing, Salesand Marketing Hospital

  3. … is completely covered by Oracle • Discovery • High performance GRID computing • BLAST Algorithm and other Search Tools • Development • Oracle Pharmaceutical Application (OPA) suite: Clinical Data Management & Remote Data Capture, Thesaurus Management, Adverse Events Reporting, Clinical Trials Management • Manufacturing, Sales and Marketing • CRF part 11 compliant Manufacturing • ERP (Financial, HR, Procurement) • Customer Relationship Management • Common foundation • Technology stack (performance, scalability, security, etc.) • Data structures • Business Intelligence and Data Warehousing

  4. Oracle LS footprint • 28 of top 30 pharma • Pfizer, GlaxoSmithKline, Merck, Johnson & Johnson, Sanofi-Aventis, AstraZeneca, Novartis, Bristol-Myers Squibb, Wyeth, Eli Lilly, Abbott Labs, Roche, Boehringer Ingelheim, Amgen, Takeda, Schering-Plough, Schering AG, Bayer, Sankyo, Yamanouchi, Novo Nordisk, Merck KGaA, Teva, Baxter, Akzo Nobel, Fujisawa, Genentech • 75% of CROs • 20 research organizations • incl. National Cancer Institute • 16 of top 20 Medical Device • Johnson and Johnson, GE Medical Systems, Baxter International, Tyco Healthcare, Medtronic, Philips Medical Systems, Roche Diagnostics, Abbott Laboratories, Guidant, Stryker, B. Braun, Boston Scientific, Becton, Dickinson & Co., Cardinal Health, Smith & Nephew

  5. OPA seen by independent research

  6. Convergence of HC & LS • What we are seeing? • Convergence of standards • Frustration with or lack of data re-use • Personalized medicine • Life Sciences focus on disease management • Emerging eHealth initiatives worldwide • Brailer initiative, NHIN, UK (National Spine), Sweden, etc. • Why is important? • Traditional data capture and EDC haven’t realized full potential benefits: process is still inherently inefficient

  7. Convergence of HC & LS • How are we helping our customers? • Driving the standards (HL7/CDISC) • Integrate clinical applications with healthcare solutions • Real time clinical information • Single data capture • Working with strategic partners who share of “patient-centric” approach to clinical data management • Data integration for drug discovery • Cohort identification • Future: Controls re-use in multiple studies

  8. Long-term strategy: Revolution • Complete migration of all HC and LS applications (Project Fusion) • Process flows through entire suite • Harmonization of all Pharma (OPA) and HC (HTB) data models • Focus on Business Intelligence • Patient-centric data • Product Lifecycle Management • Translational Research • Semantic Web (RDF) as basis of Knowledge management • Driving Healthcare – Life Sciences convergence

  9. Q & Q U E S T I O N S A N S W E R S A

  10. UNUSED / BACKUP

  11. Sustain Innovation • Increase productivity in R&D • Capitalize on internal and external information Increase Stakeholder Value • Increase profitability • Sustain top line growth • Reduce costs • Manage Risk • Ensure patient safety • Manage compliance Oracle’s approach Strategic imperatives in LS Less well understood disease mechanisms on the basis of Genomic / Proteomic research Decreasing R&D productivity and expiration of blockbuster patents Pressure in health systems to reduce cost of care and increase patient safety

  12. ResearchApplications Clinical Trails E-BusinessSuite IntegrationEngine Healthcare Transaction Base LS/HC platform: Long range vision Standards BasedMessaging Healthcare DataRepository ResearchSystems E-Business Data Repository Clinical Systems

More Related